Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;76(3):193-198.
doi: 10.5173/ceju.2023.50. Epub 2023 Jul 12.

Surgical outcomes of low-power thulium laser enucleation of prostates >80 g. One-year of follow-up

Samer Morsy  1 , Islam Kamal  1 , Alaa Meshref  1 , Mostafa Abdel-Mohsen  1 , Mahmoud Abdel-Hakim  1 , Ahmed Yehia  1
Affiliations

Surgical outcomes of low-power thulium laser enucleation of prostates >80 g. One-year of follow-up

Samer Morsy et al. Cent European J Urol. 2023.

Abstract

Introduction: The aim of this study was to assess the effectiveness of low-power thulium (30 W) and the duration necessary to eliminate adenomas at the level of the surgical capsule, as well as its impact on postoperative urinary and sexual function.

Material and methods: Patients with symptomatic benign prostatic hyperplasia (BPH), who had ThuLEP between December 2019 and March 2022 and had a prostate size >80 mL and had not responded to the medication therapy, were included. The prostate size, prostate-specific antigen (PSA), enucleation and morcellation times, postoperative International Prostate Symptom Score (IPSS), and International Index of Erectile Function-5 (IEFF-5) records at 1, 3, 6, and 12 months were among the information gathered.

Results: The average age of the 80 patients who received ThuLEP was 66.7 ±6.4 years, with a mean prostate volume of 112.65 ±19.3 mL. The mean duration for enucleation was 71 ±11 min. At the initial follow-up after one month, the mean IPSS was 8.012 ±1.78 mL and the mean Qmax enhancement was 30.16 ±4 mL s-1. In contrast to baseline, our findings demonstrated a substantial improvement in postoperative urgency and urgency urinary incontinence (UUI) (p = 0.005) but no meaningful variation in IIEF-5 score at the 12-month follow-up.

Conclusions: Low-power ThuLEP is worthwhile for therapeutic use because it effectively treats patients with large prostates with satisfactory urinary and sexual effects.Clinical trials .gov ID: NCT05494944.

Keywords: ThuLEP; benign prostatic hyperplasia; enucleation; low power.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Occurrence of stress urinary incontinence during follow-up.
Figure 2
Figure 2
Mean values of International Prostate Symptom Score during follow-up.
Figure 3
Figure 3
Mean values of International Index of Erectile Function score during follow-up.
See this image and copyright information in PMC

References

    1. Chute CG, Panser LA, Girman CJ, et al. . The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993; 150: 85-89. - PubMed
    1. Bahia LR, Araújo DV, Pepe C, Trindade M, Camargo CM, Javaroni V. Cost-effectiveness analysis of medical treatment of benign prostatic hyperplasia in the Brazilian public health system. Int Braz J Urol. 2012; 38: 595-605. - PubMed
    1. Marien T, Kadihasanoglu M, Miller NL. Holmium laser enucleation of the prostate: patient selection and perspectives. Res Rep Urol. 2016; 8: 181-192. - PMC - PubMed
    1. Wilson LC, Gilling PJ, Fraundorfer MR, et al. . A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. Eur Urol. 2006; 50: 569-573. - PubMed
    1. Montorsi F, Naspro R, Salonia A, et al. . Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center prospective randomized trial in patients with obstructive benign prostatic hyperplasia. J Urol. 2008; 179: S87-S90. - PubMed

Associated data